{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"795"}]}],"title":"day 0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1818"}]}],"title":"day1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"793"}]}],"title":"day 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"541"}]}],"title":"day 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"270"}]}],"title":"day 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"404"}]}],"title":"day 5"},{"categories":[{"measurements":[{"groupId":"OG000","value":"400"}]}],"title":"day 6"},{"categories":[{"measurements":[{"groupId":"OG000","value":"429"}]}],"title":"day 7"},{"categories":[{"measurements":[{"groupId":"OG000","value":"231"}]}],"title":"day 8"},{"categories":[{"measurements":[{"groupId":"OG000","value":"59"}]}],"title":"day 9"},{"categories":[{"measurements":[{"groupId":"OG000","value":"49"}]}],"title":"day10"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36"}]}],"title":"day11"},{"categories":[{"measurements":[{"groupId":"OG000","value":"105"}]}],"title":"≥day12"}],"denomUnitsSelected":"Participants","denoms":[{"counts":[{"groupId":"OG000","value":"1447"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"5930"}],"units":"cycles"}],"description":"Objective 2: To describe EP2006 primary or secondary prophylaxis patterns for FN over up to 6 cycles of chemotherapy, with or without prior, concurrent, or later radiotherapy or surgery.\n\nTable presents number of cycles by day after chemotherapy.","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG000","title":"EP2006"}],"paramType":"NUMBER","populationDescription":"Cycles of patients in evaluable sample with day of study drug initiation","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"EP2006 Day of Initiation: Cycle Distribution","type":"PRIMARY","typeUnitsAnalyzed":"cycles","unitOfMeasure":"cycles"}